French Microbiome Startup Gets €10M to Start Clinical Trials

23/03/2016 - 3 minutes

MaaT Pharma (France) has raised €10M in a series A round, which will allow it to start clinical development of its autologous therapy for imbalance of the Gut Microbiome.

maat_microbiome_autologous_therapy_fmtMaaT Pharma is developing microbiome-based therapies with an autologous (self-sourced) approach. This means that the patient suffering from dysbiosis is treated with their own microbiome, samples of which were stored when the patient was healthy.

Dysbiosis is an imbalance in the normal microbiota living in the human gut that can lead to difficult opportunitistic infections.

Since its creation in late 2014, MaaT Pharma has attracted significant attention. This Lyon-based startup had already received €2M from the world-first €160M Microbiome Fund, and developed its pre-clinical proof of concept in collaboration with the French National Institute of Agricultural Research (INRA).

MaaT has also won the ‘iiAwards’ startup competition and was selected for the TOP10 in the Big Booster programme.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member